New drug combo targets tough sarcomas in kids and adults

NCT ID NCT06156410

Recruiting now Disease control Sponsor: Children's Hospital of Philadelphia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests the safety and best dose of cabozantinib combined with high-dose ifosfamide in 30 children and adults with sarcomas (like Ewing sarcoma or osteosarcoma) that have returned or not responded to standard chemotherapy. The goal is to find a dose that controls the disease with manageable side effects. Participants must have measurable tumors and have already tried traditional chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma osteosarcoma Recurrence sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EWING SARCOMA OSTEOSARCOMA SARCOMAS

Contacts and locations

Show contact details

Locations

Children's Hospital Colorado
RECRUITING

Aurora, Colorado, 80045, United States
Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of California San Francisco
RECRUITING

San Francisco, California, 94143, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.